Jefferies Group’s Acorda Therapeutics ACOR Stock Holding History

Jefferies Group’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-417	Closed	-$102K	–	2805
2019 Q4	$102K	Buy	417 +103	+33%	+$26K	﹤0.01%	2385
2019 Q3	$108K	Sell	314 -100	-24%	-$54.4K	﹤0.01%	2498
2019 Q2	$381K	Buy	414 +106	+34%	+$130K	﹤0.01%	1806
2019 Q1	$491K	Sell	308 -442	-59%	-$796K	﹤0.01%	1595
2018 Q4	$1.4M	Sell	750 -75	-9%	-$163K	0.01%	995
2018 Q3	$1.95M	Buy	825 +304	+58%	+$941K	0.01%	994
2018 Q2	$1.79M	Buy	+521	New	+$1.6M	0.01%	948
2017 Q2	–	Sell	-32	Closed	-$81K	–	2671
2017 Q1	$81K	Buy	+32	New	+$92.1K	﹤0.01%	2150
2015 Q3	–	Sell	-1	Closed	-$3K	–	3226
2015 Q2	$3K	Buy	+1	New	+$3.86K	﹤0.01%	3110
2014 Q4	–	Sell	-17	Closed	-$70K	–	2436
2014 Q3	$70K	Buy	+17	New	+$63.8K	﹤0.01%	1952

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jefferies Group's ACOR Position: Q1 2020 in Review

Jefferies Group sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 417 shares — an estimated $102K sold.

Jefferies Group first reported a position in ACOR in Q3 2014 and held it in 10 quarters. The position peaked at $1.95M in Q3 2018. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

Jefferies Group reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
Jefferies Group sold 417 Acorda Therapeutics shares in Q1 2020, an estimated $102K.
Jefferies Group first reported a position in Acorda Therapeutics in Q3 2014 and held it in 10 quarters.
Jefferies Group's Acorda Therapeutics position peaked at $1.95M in Q3 2018.
106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.